H. Jaeger

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

Christoph Wyen, Heidy Hendra, M. Vogel et al. · Journal of Antimicrobial Chemotherapy · 2008 · 170 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens

Christoph Wyen, Heidy Hendra, Marco Siccardi et al. · Journal of Antimicrobial Chemotherapy · 2011 · 104 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Construction of Shuttle Plasmids Which Can Be Efficiently Mobilized from Escherichia coli into the Chromatically Adapting Cyanobacterium, Fremyella diplosiphon

John Cobley, Edward H Zerweck, Anahita Minoo Mody et al. · Plasmid · 1993 · 97 citations

Life Sciences, Genetics, Microbiology +16

Risk factors for the HIV‐associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment

Stefan Mauss, Michael Corzillius, Eva Wolf et al. · HIV Medicine · 2002 · 64 citations

Public Health, Endocrinology, Health Sciences +16

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Constance Delaugerre, Philippe Flandre, Marie‐Laure Chaix et al. · Antimicrobial Agents and Chemotherapy · 2009 · 54 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17